Clinical Trial Update: A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses [Phase 1]

View source ↗

Summary

Phase 1 pharmacology study evaluating a once-weekly brexpiprazole oral formulation given as single and multiple doses in schizophrenia, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• REXULTI (brexpiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2024-08-05